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Abstract 26 
 27 
RNA de novo synthesized are under the regulation of multiple post-transcriptional 28 
processes by a variety of RNA-binding proteins.  The influenza virus genome 29 
consists of single-stranded RNAs and exists as viral ribonucleoprotein complexes 30 
(vRNP).  After the replication of vRNP in the nucleus, vRNP is exported to the 31 
cytoplasm and then reaches the budding site beneath cell surface mediated by 32 
Rab11a-positive recycling endosomes along microtubules.  However, the 33 
regulatory mechanisms of post-replicational processes of vRNP are largely 34 
unknown.  Here, we identified, as a novel vRNP-interacting protein, Y-box 35 
binding protein-1 (YB-1), a cellular protein that is involved in regulation of cellular 36 
transcription and translation.  YB-1 translocated to the nucleus from the 37 
cytoplasm and accumulated in PML nuclear bodies in response to influenza virus 38 
infection.  vRNP assembled into the exporting complexes with YB-1 at PML 39 
nuclear bodies.  After nuclear-export, using YB-1 knockdown cells and in vitro 40 
reconstituted systems, YB-1 was shown to be required for the interaction of 41 
nuclear-exported vRNP with microtubules around the microtubule organization 42 
center (MTOC), where Rab11a-positive recycling endosomes were located.  43 
Further, we also found that YB-1 overexpression stimulates the production of 44 
progeny virions in an Rab11a-dependent manner.  Taken altogether, we propose 45 
that YB-1 is a porter that leads vRNP to microtubules from the nucleus and put it 46 
on the vesicular trafficking system. 47 
48 
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Introduction 49 
 50 
In general, RNA transcripts form ribonulceoprotein (RNP) complexes with a number of 51 
RNA-binding proteins.  The destiny of the RNP complexes in terms of localization, 52 
stability, and translational control is regulated by their protein constituents (16, 21, 33). 53 
The genome of influenza type A viruses consists of eight-segmented and 54 
single-stranded RNAs of negative polarity (vRNA).  vRNA exists as RNP complexes 55 
(designated vRNP) with viral RNA-dependent RNA polymerase consisting of three 56 
subunits—PB1, PB2, and PA—and nucleoprotein (NP).  vRNA is transcribed into 57 
mRNA and replicated through cRNA (full-sized complementary copy of vRNA) into a 58 
large number of progeny vRNAs in the nucleus (reviewed in 49).  The replicated vRNA 59 
is assembled into vRNP, and then the progeny vRNP interacts with M1.  The 60 
vRNP-M1 complex is nuclear-exported through the CRM1-dependent pathway mediated 61 
by the interaction of vRNP-M1 complex with NS2 (also called as NEP), which is a viral 62 
protein containing an NES (19, 52, 54, 77).  After the nuclear-export, it is quite likely 63 
that the progeny vRNP accumulates in the microtubule-organizing center (MTOC) and 64 
then moves to the budding site beneath the cell surface along microtubules through 65 
Rab11a-dependent vesicular trafficking systems (28, 45).  Finally, a set of eight 66 
segments of vRNA is incorporated into a progeny virion with other viral structural 67 
proteins (51, 53, 79). 68 
The Rab11a-positive recycling endosome is important for the delivery of 69 
membranes and core polarity proteins to the lateral cell surface (reviewed in 25, 42, 74), 70 
leading to the construction of plasma membrane domains and epithelial cell polarity 71 
through binding to motor proteins along cytoskeleton (75).  The Rab11a-positive 72 
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recycling endosome is located typically in close proximity to the nucleus and associated 73 
with the microtubule organizing center (MTOC).  Recent reports demonstrate that a 74 
number of viruses, including influenza virus (1, 17, 47), human cytomegalovirus (36), 75 
hantavirus (61), respiratory syncytial virus (6, 73), and Sendai virus (9), employ the 76 
Rab11a-positive recycling endosomes during the egress.  However, the targeting 77 
mechanism of cargo molecules including influenza virus vRNP to the Rab11a-positive 78 
recycling endosome is still poorly understood. 79 
Since influenza virus genome encodes only eleven viral proteins, the virus 80 
has to hijack cellular functions/machineries consisting of numerous cellular proteins to 81 
achieve every infection processes.  Therefore, to understand the regulatory mechanism 82 
of the localization and intracellular transport of vRNP, identification and 83 
characterization of viral and cellular proteins involved in these processes are required.  84 
Here, we identified as a novel vRNP-interacting protein, Y-box binding protein-1 85 
(YB-1), a cellular protein that is involved in regulation of cellular transcription and 86 
translation (41).  In the nucleus, YB-1 functions as a Y-box promoter element-binding 87 
transcription factor (34, 37, 41).  However, a major portion of YB-1 localizes in the 88 
cytoplasm and regulates mRNA translation and degradation as a major component of 89 
cellular mRNA ribonucleoprotein (mRNP).  A sudden translational arrest in response 90 
to a variety of stresses is accompanied by the formation of stress granules (SGs) and an 91 
increase in the number of mRNA processing bodies (P-bodies) to reprogram gene 92 
expressions post-transcriptionally (3).  It is suggested that SGs are aggregates of 93 
translationally inactive mRNAs containing stalled translation initiation complexes while 94 
P-bodies are mRNP aggregates with proteins involved in mRNA decay and translational 95 
repression (2, 21).  YB-1 accumulates in these cytoplasmic structures (2) and acts as 96 
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either translational activator or inhibitor depending on its amount bound to the target 97 
mRNP (55).  Therefore, it is proposed that YB-1 determines the fate of cellular mRNPs 98 
from their synthesis to destruction. 99 
Here, we found that YB-1 translocates to the nucleus in response to influenza 100 
virus infection.  The nuclear-imported YB-1 accumulates in nuclear speckles, 101 
promyelocytic leukemia nuclear bodies (PML-NBs), together with vRNP, M1, and NS2 102 
in the presence of leptomycin B (LMB), a potent inhibitor of CRM1, suggesting that 103 
YB-1 is associated with the vRNP export complexes in the nucleus.  At late phases of 104 
infection, YB-1 was found in perinuclear granules with the newly synthesized vRNP, 105 
and accumulated in Rab11a-positive recycling endosomes along microtubules.  Further, 106 
we found that YB-1 mediates the interaction of vRNP with microtubules.  Collectively, 107 
we propose that YB-1 functions as a porter that facilitates the association of the progeny 108 
vRNP with microtubules, thereby leading the ride of vRNP onto Rab11a-positivie 109 
recycling endosomes. 110 
 111 
112 
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MATERIALS AND METHODS 113 
Biological materials.  vRNP was prepared from purified influenza A/Puerto Rico/8/34 114 
(A/PR/8/34) virus as previously described (66).  Rabbit polyclonal antibodies against 115 
YB-1, RAP55, RCK, PB1, PB2, PA, M1, and NP, and rat antibody against NS2 were 116 
prepared as previously described (30, 31, 40, 50, 71, 72, 77).  Rabbit polyclonal 117 
antibodies against TIAR, PML (SANTA CRUZ BIOTECHNOLOGY), Rab11a 118 
(Invitrogen), and mouse monoclonal antibodies against -tubulin (Sigma) and PML 119 
(SANTA CRUZ BIOTECHNOLOGY) were purchased.  Anti-SeV antibody and 120 
anti-M1 monoclonal antibody were generously gifted from Dr. A. Kato (National 121 
Institute of Infectious Diseases, Japan) and Drs. S. Hongo and K. Sugawara (Yamagata 122 
University), respectively.  MDCK, 293T, and HeLa cells were grown in Minimal 123 
Essential Medium (MEM) containing 10% fetal bovine serum.  For the construction of 124 
plasmids expressing His-YB-1 and FLAG--tubulin, the cDNAs were amplified with a 125 
primer set, 5′-GGAATTCCATATGAGCAGCGAGGCCGAGACCCAGC-3′ and 126 
5′-GAACCGCTCGAGCTCAGCCCCGCCCTGCTCAGCCTCGGGAG-3′ for YB-1 127 
and a primer set, 128 
5′-CGCCACCATGGACTACAAGGATGACGACGACAAGCATATGCGTGAGTGCA129 
TCTCC-3′ and 5′-CTATTAATACTCTTCACCCTCAT-3′ for -tubulin and cDNAs 130 
reverse-transcribed from HeLa total RNA using oligo(dT)20 primer as a template, 131 
respectively.  YB-1 cDNA was cloned into pET24b plasmid, and the resultant plasmid 132 
was then used as a template to amplify FLAG-YB-1 cDNA with a primer set, 133 
5′-GCCGCCACCATGGACTACAAGGATGACGACGACAAGCATATGAGCAGCGA134 
GGCCGA-3′ and 5′-CCCGGATCCTATTACTCAGCCCCGCCCTG-3′.  FLAG-YB-1 135 
and FLAG--tubulin cDNAs were cloned into pCAGGS plasmid.  The cDNA 136 
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fragments of YB-1 deletion mutants were amplified with primer sets, 137 
5′-GCAGATATCATGAGCAGCGAGGCCGA-3′ and 138 
5′-TGCGGATCCCTACCATGGCCCGCCGGCAGGC-3′ for A/P domain (1-50 a.a.), 139 
5′-GCAGATATCATGAGCAGCGAGGCCGA-3′ and 140 
5′-TGCGGATCCTTAACCAGGACCTGTAACATT-3′ for A/B domain (1-129 a.a.), 141 
5′-GCAGATATCGACAAGAAGGTCATCGCAA-3′ and 142 
5′-CCCGGATCCTATTACTCAGCCCCGCCCTG-3′ for A/P domain (51-324 a.a.), 143 
and 5′-GCACCATGGGATATCGGTGTTCCAGTTCAAGGC-3′ and 144 
5′-CCCGGATCCTATTACTCAGCCCCGCCCTG-3′ for A/B domain (130-324 a.a.), 145 
and then cloned into pGEX-6P plasmid, respectively.  To establish HeLa cell lines 146 
constitutively expressing either FLAG-YB-1 or FLAG--tubulin, HeLa cells transfected 147 
with pSV2-Neo and either pCAGGS-FLAG-YB-1 or pCAGGS-FLAG--tubulin were 148 
selected by growing in the presence of 1 mg/ml G418 for two weeks, and then the 149 
G418-resistant colonies were isolated.  Recombinant His-YB-1 and GST-fused 150 
deletion mutants of YB-1 were purified according to the manufacturer’s protocol.  In 151 
addition, to remove the bacterial RNA possibly bound to YB-1, we treated recombinant 152 
YB-1 with RNase A before purification. 153 
LC-MS analysis.  Molecular masses of trypsin-digested peptides from 154 
co-immunoprecipitated proteins with NP were calculated by liquid 155 
chromatography-coupled mass spectrometry (LC-MS) analysis (Thermo) after reduction 156 
and alkylation of cysteine residues.  Assignment of observed ions was done by Mascot 157 
search software. 158 
Cellular localization of viral RNAs and proteins.  Indirect 159 
immunofluorescence assays and fluorescence in situ hybridization (FISH) assays were 160 
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carried out as previously described (28).  Briefly, cells infected with A/PR/8/34 at 161 
multiplicity of infection (moi) of 10 were fixed by 1% parafolmaldehyde (PFA) for 5 162 
min, and then pre-permeabilized with 0.01% digitonin in PBS for 5 min on ice.  After 163 
washing with PBS, cells were fixed in 4% PFA for 10 min and permeabilized with 0.5% 164 
Triton X-100 in PBS for 5 min on ice.  After incubation in PBS containing 1% bovine 165 
serum albumin (BSA) for 1 h, coverslips were incubated with each antibody for 1 h, and 166 
then with Alexa Fluor 488- or 568-conjugated anti-rabbit, rat, and mouse IgG antibodies 167 
(Invitrogen), respectively.  After the indirect immunofluorescence assays, FISH assays 168 
were performed using RNA probes complementary to the segment 1 vRNA and 169 
cRNA/mRNA, respectively.  Images were acquired by confocal laser scanning 170 
microscope (Zeiss).  Each micrograph is a confocal section taken at the same level of 171 
focus among samples, so that nuclei were fully observed with a maximum diameter. 172 
Immunoprecipitation.  Infected cells crosslinked with 0.5% formaldehyde 173 
for 10 min at room temperature were lysed by sonication in a buffer containing 20 mM 174 
Tris-HCl (pH 7.9), 100 mM NaCl, 30 mM KCl, 0.1% NP-40, and 1 mM EDTA.  The 175 
lysates were subjected to centrifugation at 12,000 xg, and the supernatant fractions were 176 
subjected to immunoprecipitation with antibodies where indicated.  For detection of 177 
viral RNAs immunoprecipitated with YB-1 from infected cells, the immunoprecipitates 178 
were subjected to reverse-crosslinking in a buffer containing 50 mM Tris-HCl (pH 7.9), 179 
5 mM EDTA, 50 mM DTT, and 1% SDS for 45 min at 70ºC.  After 180 
reverse-crosslinking, viral RNAs were purified by phenol-chloroform extraction 181 
followed by ethanol precipitation, and then reverse-transcribed with primers to 182 
determine the level of vRNA (5′-GACGATGCAACGGCTGGTCTG-3′, which 183 
corresponds to the segment 5 cRNA between nucleotide sequence positions 424 and 184 
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444), cRNA (5′-AGTAGAAACAAGGGTATTTTTCTTTA-3′, which is complementary 185 
to the segment 5 cRNA between nucleotide sequence positions 1540 and 1565), and that 186 
of viral mRNA (oligo(dT)20 for poly(A) tail).  The synthesized single-stranded cDNAs 187 
were subjected to quantitative real time PCR analysis (Thermal Cycler Dice Real Time 188 
System TP800; TaKaRa) with two specific primers, 189 
5′-GACGATGCAACGGCTGGTCTG-3′, which corresponds to the segment 5 cRNA 190 
between nucleotide sequence positions 424 and 444, and 191 
5′-AGCATTGTTCCAACTCCTTT-3′, which is complementary to the segment 5 cRNA 192 
between nucleotide sequence positions 595 and 614. 193 
Gene silencing mediated by siRNA.  Short interfering RNA (siRNA) against 194 
Rab11a and YB-1 genes were purchased from Invitrogen, respectively.  Cells (5 x 105 195 
cells) were transfected with 30 pmol of siRNA using Lipofectamine RNAi MAX 196 
(Invitrogen) according to the manufacturer’s protocol. 197 
Reconstruction of vRNP-microtubules complex mediated by YB-1.  198 
Cellular tubulin and microtubule-associated protein(s) (MAPs) purified from bovine 199 
brain as previously described (67) were kindly provided from K. Mizumoto (Kitasato 200 
University).  The purified tubulin proteins (40 g) were assembled into microtubules 201 
by incubating at 37ºC for 20 min in a buffer containing 50 mM PIPES-NaOH (pH 6.8), 202 
1 mM EGTA, 5 mM MgCl2, 20% Glycerol, 1 mM GTP, and 20 M Taxol.  The 203 
reconstituted microtubules were precipitated by centrifugation at 32,000 rpm at 20ºC for 204 
20 min in SW55Ti rotor (Beckman) to remove the monomeric tubulin proteins.  The 205 
precipitates were resuspended in a buffer containing 50 mM HEPES-NaOH (pH 7.9), 50 206 
mM KCl, 20 M Taxol, and 0.5% BSA, and then incubated with either vRNP or 207 
YB-1-vRNP complexes.  The vRNP complexes were immunoprecipitated with anti-NP 208 
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antibody, and then the co-precipitated microtubules were detected by western blotting 209 
assay with anti--tubulin antibody. 210 
211 
 11
RESULTS 212 
 213 
Identification of YB-1 as a novel vRNP-interacting protein.  To get further insight 214 
in the regulatory mechanism of vRNP function, we tried to determine a novel cellular 215 
protein(s) that interacts with vRNP.  At 8 h post infection (hpi), infected cell lysates 216 
were subjected to immunoprecipitation using anti-NP antibody, and then the precipitated 217 
proteins were subjected to LC-MS analysis (Fig. 1A).  We found that viral proteins, 218 
PB1, PB2, PA, M1, and NS1, were co-precipitated with NP as expected (32, 39, 56, 58, 219 
59), suggesting that not only NP but also vRNP were immunoprecipitated in this 220 
experiment.  In addition to these viral proteins, we also identified a number of cellular 221 
proteins interacting with vRNP as previously reported (Table 1) (29, 43, 44, 46, 76).  It 222 
is noted that YB-1, a major component of cellular mRNP, was also identified as a novel 223 
vRNP-interacting protein.  YB-1 regulates the life time and the translational activity of 224 
cellular mRNP depending on the amount of YB-1 on a target mRNA (22, 55).  Further, 225 
it is proposed that YB-1-bound mRNP particles interact with microtubules, but a precise 226 
role(s) of YB-1 has not yet been uncovered (11, 12).  Thus, we tried to examine 227 
whether YB-1 regulates the fate of vRNP. 228 
YB-1 localizes predominantly in the cytoplasm, but translocates to the nucleus 229 
to regulate transcription in response to environmental stimuli such as DNA-damaging 230 
agents, UV irradiation, hyperthermia, and serum stimulation (34).  More importantly, 231 
YB-1 is one of the components of SGs and P-bodies, which are cytoplasmic 232 
compartments possibly involved in the regulation of translation under stress conditions 233 
(78).  Viral infection also gives a stressful environment to cells.  To elucidate the 234 
biological significance of the interaction of vRNP with YB-1, we examined the 235 
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intracellular localization of YB-1 in influenza virus-infected cells by indirect 236 
immunofluorescence assays using anti-YB-1 antibody (Fig. 1B).  The vRNA was also 237 
counterstained by fluorescence in situ hybridization (FISH) method (28).  YB-1 238 
localized at the cytoplasm in infected cells at 4 hpi as did it in mock-infected cells.  239 
Along with the progression of infection, YB-1 was imported to the nucleus and became 240 
accumulated in unknown nuclear speckles at 8 hpi.  At 12 hpi, a portion of YB-1 was 241 
found in unknown cytoplasmic granules with the exported progeny vRNA.  Since 242 
these cytoplasmic granules of YB-1 were not found in the presence of LMB, a potent 243 
inhibitor of CRM1, it is likely that YB-1 is exported with vRNA from the nucleus (Fig. 244 
1B).  Furthermore, the translocation of YB-1 upon influenza virus infection may not be 245 
involved in the innate immunity since the localization of YB-1 was not changed in 246 
Sendai virus-infected cells (Fig. 1B).  Next, we examined the intracellular localization 247 
of RAP55, RCK/p54, and TIAR proteins, which are components of cellular mRNP and 248 
accumulate in SGs and P-bodies (2).  In contrast to YB-1, we did not find any 249 
localization changes of these proteins in response to infection (Fig. 1C).  Thus, the 250 
translocation of YB-1 found in infected cells may not be involved in a function as a 251 
component of SGs and P-bodies. 252 
Interaction of YB-1 with vRNP exporting complexes.  Progeny vRNP is 253 
exported to the cytoplasm from the nucleus through the CRM1-dependent pathway by 254 
assembling export complexes with viral proteins, M1 and NS2 (19, 52, 54, 77).  Since 255 
YB-1 may be exported to the cytoplasm together with vRNP, it is assumed that YB-1 256 
interacts with vRNP export complexes in the nucleus.  To address this, we examined 257 
the co-localization of YB-1 with M1 and NS2.  We found that M1 but not NS2 258 
accumulated in the nuclear speckles with YB-1 at 8 hpi (Fig. 2A).  Since a major 259 
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portion of the progeny vRNA and NS2 was localized in the cytoplasm (Fig. 1B and 2A), 260 
the newly synthesized vRNP may be exported to the cytoplasm immediately after the 261 
export complex formation.  Thus, we examined the localization of vRNA and NS2 in 262 
the LMB-treated cells.  By inhibition of the CRM1-dependent export pathway, vRNA 263 
was accumulated in the nuclear speckles with YB-1, M1, and NS2 (Fig. 2B).  264 
Previously, it was reported that a small portion of M1 and NS2 may localize in 265 
PML-NBs (62, 64).  It is shown that the overexpression of PML suppresses the 266 
influenza virus proliferation (10, 27), suggesting that PML-NBs may contribute to the 267 
cellular antiviral response.  However, the role of PML-NBs remains controversial since 268 
influenza virus replicates normally in cells lacking PML gene (20).  As expected, in the 269 
presence of LMB, we found that vRNA and YB-1 were partially associated with 270 
PML-NBs (Fig. 2C).  Taken altogether, it is possible that the nuclear-imported YB-1 271 
interacts with the vRNP export complexes in PML-NBs, and then YB-1 is subsequently 272 
exported from the nucleus with vRNP. 273 
 Influenza virus produces three different RNAs, i.e., vRNA, cRNA, and viral 274 
mRNA.  Both vRNA and cRNA form ribonucleoprotein complexes with the viral 275 
polymerase and NP, whereas vRNA, but not cRNA, is found in the cytoplasm (26) and 276 
packaged into the virions.  In contrast, the viral mRNA interacts with cellular 277 
mRNA-binding proteins, and is exported through the REF/Aly pathway generally used 278 
by cellular mRNAs (4, 57).  To examine the specific interaction of YB-1 with viral 279 
RNAs, we visualized positive-sense RNAs (cRNA and viral mRNA) by FISH assays.  280 
The intracellular localization of positive-sense RNAs was not changed by LMB 281 
treatment as previously reported (57), and the FISH signals were not co-localized with 282 
YB-1 in the absence or presence of LMB (Fig. 3A).  Further to show quantitative 283 
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results, we performed immunoprecipitation assays with cell lysates prepared from cells 284 
constitutively expressing FLAG-YB-1 using anti-FLAG antibody as described in 285 
MATERIALS AND METHODS.  We found that vRNA interacted with YB-1, but 286 
neither cRNA nor viral mRNA did in infected cells (Fig. 3B).  Thus, it is quite likely 287 
that YB-1 is involved in the functional regulation of vRNP, but neither cRNP nor viral 288 
mRNP. 289 
Interaction of the YB-1-vRNP complex with Rab11a-positive recycling 290 
endosomes along microtubules.  At 12 hpi, YB-1 was partially co-localized with the 291 
nuclear-exported vRNA in the cytoplasm (Fig. 1B).  Recent studies have suggested 292 
that the progeny vRNP is transported to the plasma membrane along microtubules via 293 
Rab11a-positive recycling endosomes (1, 17, 47).  Further, it is reported that YB-1 294 
interacts with microtubules (12).  Based on these, we examined whether YB-1 295 
accumulates in microtubules with vRNP (Fig. 4).  We found that the cytoplasmic 296 
punctate signals of YB-1 in perinuclear regions were co-localized with -tubulin (Fig. 297 
4A).  Then, we examined the interaction of YB-1 with microtubules, Rab11a, and 298 
vRNP by immunoprecipitation assays.  YB-1 interacted with -tubulin, but hardly 299 
with Rab11a in mock-infected cells (Fig. 4B, lane 3).  In contrast, the interaction of 300 
YB-1 with Rab11a was significantly increased in infected cells (Fig. 4B, lane 6).  To 301 
address whether the vRNP-YB-1 complexes accumulate in microtubules with Rab11a, 302 
the proteins co-precipitated with YB-1 from infected lysates (Fig. 4B, lane 6) were 303 
eluted and then subjected to re-immunoprecipitation with anti-NP antibody (Fig. 4C).  304 
Since -tubulin and Rab11a were immunoprecipitated with anti-NP antibody (Fig. 4C, 305 
lane 3), it is quite likely that the progeny vRNP is accumulated on Rab11a-positive 306 
recycling endosomes with YB-1 along microtubules. 307 
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YB-1 is a positive factor for Rab11a-dependent virus production.  It is 308 
shown that Rab11a is required for the transport of vRNP to the apical plasma membrane 309 
and thereby affects the production of progeny virions (1, 17, 47).  Since YB-1 binds to 310 
Rab11a together with vRNP (Fig. 4C), it is assumed that YB-1 is involved in production 311 
of progeny virions through the Rab11a-positive recycling endosome pathway.  To 312 
address this, the effect of YB-1 overexpression on the virus titer was examined using 313 
siRNA-mediated Rab11a knockdown (KD) cells (Fig. 5).  The transfection efficiency 314 
was approximately 60%.  The amount of exogenously overexpressed FLAG-YB-1 was 315 
3-fold higher than that of endogenous YB-1, and the expression level of Rab11a in KD 316 
cells decreased to approximately 30% of that of control cells transfected with the 317 
non-targeting siRNA (Fig. 5A).  The expression level of viral proteins was found to be 318 
virtually unchanged by YB-1 overexpression (Fig. 5B).  We found that the amount of 319 
infectious virions produced from cells overexpressing YB-1 was significantly increased 320 
as compared to cells transfected with empty plasmid, whereas the virus titer was slightly 321 
enhanced by YB-1 overexpression in Rab11a KD cells (Fig. 5C).  Further, the slopes 322 
of the lines in panel C were determined to compare the efficiency of virus production 323 
(Fig. 5D).  This result shows that the production of infectious viruses was increased by 324 
4.8-fold by the YB-1 overexpression, but the stimulatory activity of YB-1 was reduced 325 
by 1.9-fold by Rab11a KD (Fig. 5D).  Therefore, it is concluded that YB-1 stimulates 326 
the production of infectious viruses in the Rab11a-dependent manner.  We also tried to 327 
measure the amount of infectious virions produced from YB-1 KD cells.  But, YB-1 328 
KD cells tend to die by influenza virus infection after 16-20 hpi (data not shown).  329 
Thus, it was difficult to demonstrate the effect of YB-1 on the virus titer using YB-1 330 
siRNA. 331 
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YB-1 functions as a porter for vRNP to direct it to microtubules.  Figures 332 
4 and 5 suggested that YB-1 functions in the vRNP transport through the 333 
Rab11a-positive recycling endosome pathway along microtubules.  Next, we tried to 334 
demonstrate whether YB-1 functions as a transporter of vRNP to microtubules using 335 
siRNA-mediated gene silencing (Fig. 6).  At 48 h post transfection of YB-1 siRNA, the 336 
expression level of YB-1 in KD cells decreased to 25% of that of control cells (Fig. 6A).  337 
There were no differences found in the accumulation level of viral proteins (Fig. 6B), 338 
vRNA, and viral mRNA (Fig. 6C) between control and YB-1 KD cells.  Previous 339 
reports showed that the nuclear-exported vRNP complexes accumulate at MTOC around 340 
the perinucleus (45) with Rab11a-positive recycling endosomes (1, 17, 47).  We 341 
carried out FISH assays to examine whether vRNP complexes localize around the 342 
perinucleus in YB-1 KD cells at 8 hpi (Fig. 6D and 6E).  A major portion (81.5±7.2%) 343 
of vRNA was found as diffusive signals in YB-1 KD cells.  Thus, it is quite likely that 344 
YB-1 stimulates the accumulation of vRNP at MTOC.  As shown in Fig. 2C, the 345 
replicated vRNA associated with PML-NBs in the presence of LMB.  Since vRNA 346 
accumulated in PML-NBs even in YB-1 KD cells with LMB treatment (Fig. 6D), it is 347 
strongly suggested that YB-1 is not involved in the association between vRNP and 348 
PML-NBs.  It is also suggested that YB-1 does not play a role in the vRNP export from 349 
the nucleus to the cytoplasm since vRNA was found predominantly in the cytoplasm of 350 
YB-1 KD cells (Fig. 6E). 351 
 YB-1 interacts with vRNP (Fig. 1A and 4B), but it is unclear whether YB-1 352 
interacts directly with one or more of vRNP components, that is, viral polymerase 353 
complexes, NP, and vRNA.  To test this, we performed pull-down assays with purified 354 
vRNP and His-YB-1 using Ni-NTA resin (Fig. 7A).  Not only viral polymerase 355 
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subunits but also NP were co-precipitated with YB-1 (lane 6), demonstrating that YB-1 356 
interacts directly with vRNP.  Since YB-1 has a single-stranded RNA binding activity, 357 
it is possible that YB-1 binds to vRNA.  To address this, vRNP treated with 358 
micrococcal nuclease (mnRNP) to deplete vRNA was also subjected to the pull-down 359 
assay with His-YB-1.  We found that each viral polymerase subunit but not NP from 360 
mnRNP was co-precipitated with YB-1 (lane 9), suggesting that YB-1 interacts with 361 
viral polymerase complexes.  YB-1 consists of three domains: the N-terminal domain, 362 
the cold shock domain (CSD), and the C-terminal tail domain.  The CSD has the 363 
well-characterized RNA-binding motifs RNP-1 and RNP-2, and thereby functions as a 364 
nucleic acid-binding domain.  The N-terminal domain is rich in alanine and proline 365 
(A/P domain), and the C-terminal domain contains alternating clusters of positively and 366 
negatively charged amino acid residues (A/B domain).  All of the three domains are 367 
involved in the interaction with a number of cellular proteins (reviewed in 18).  To 368 
further characterize the interaction between YB-1 and vRNP, we carried out pull-down 369 
assays with GST-fused deletion mutants of YB-1 and vRNP (Fig, 7B).  We found that 370 
PB1 is co-precipitated with the mutants harboring the A/B domain (lanes 5 and 6; A/P 371 
and A/B), suggesting that YB-1 interacts with vRNP through the A/B domain.  Next, 372 
we tried to demonstrate whether YB-1 recruits vRNP on microtubules in vitro.  373 
Reconstituted microtubules were incubated with either vRNP or YB-1-vRNP complex, 374 
and then subjected to immunoprecipitation using anti-NP antibody (Fig. 7B).  We 375 
found that microtubules were hardly co-precipitated with vRNP in the absence of YB-1 376 
(lane 3).  In sharp contrast, in the presence of YB-1, the interaction of vRNP with 377 
microtubules was increased by approximately 3-fold (lane 4).  Finally, we carried out 378 
immunoprecipitation assays with cell lysates prepared from cells constitutively 379 
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expressing FLAG--tubulin with or without YB-1 KD (Fig. 7C).  We found that PB1 380 
was immunoprecipitated with FLAG--tubulin from control lysates (lane 3), but 381 
slightly from YB-1 KD lysates (lane 6).  Therefore, it could be concluded that YB-1 is 382 
required for the accumulation of vRNP on microtubules.  Taken altogether, we would 383 
propose that YB-1 interacts directly with vRNP and functions as a porter that facilitates 384 
the binding of vRNP with microtubules, where vRNP is led to Rab11a-positivie 385 
recycling endosomes. 386 
387 
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DISCUSSION 388 
 389 
We have identified YB-1, a cellular DNA/RNA-binding protein, as a vRNP-interacting 390 
protein (Fig. 1A).  YB-1 was found to be relocalized to the nucleus from the cytoplasm 391 
and associated with PML-NBs along with the progression of virus infection (Fig. 1B).  392 
Previous reports showed that the nuclear-import of YB-1 requires phosphorylation by 393 
PKC (35), Jak1 (15), and Akt kinases (69).  The other mechanism for nuclear-import 394 
of YB-1 is thought to be triggered by a proteolytic cleavage by 20S proteasome to 395 
separate the C-terminal fragment (220-324 a.a.) containing a cytoplasmic retention 396 
signal (68).  When we performed immunofluorescence assays with each antibody 397 
recognizing either N-terminus (1-13 a.a.; used in this study) or C-terminus (307-324 398 
a.a.; purchased from Sigma), the YB-1 nuclear-import was found only when the 399 
antibody recognizing N-terminus was used (data not shown).  However, we found that 400 
vRNP complexes interact with full-length YB-1 (Fig. 1A), suggesting that the 20S 401 
proteasome-mediated processing of YB-1 may not always be required in influenza 402 
virus-infected cells.  Therefore, it is possible that the recognition specificity of our 403 
antibody is due to the unknown conformational change of YB-1 possibly induced by the 404 
phosphorylation and/or the interaction with cellular and/or viral proteins.  405 
Identification of a signaling pathway and interacting proteins responsible for the 406 
nuclear-import of YB-1 upon influenza virus infection is needed. 407 
 PML-NBs are highly dynamic structures that are disrupted or changed in their 408 
morphology in response to environmental stimuli (38).  The genomes of several DNA 409 
viruses have been shown to be localized and transcribed in the vicinity of PML-NBs (13, 410 
23, 24).  In most cases, virus-encoded regulatory proteins localize at PML-NBs and 411 
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disrupt PML-NBs for successful infection, suggesting a negative role for PML-NBs in 412 
virus growth (13, 23, 24).  In addition to the putative function of PML-NBs during 413 
virus infection, it is postulated that PML-NBs are implicated in cellular gene 414 
transcription, tumor suppression, proteasomal degradation, cellular senescence, 415 
apoptosis, and DNA repair (14, 38).  It is proposed that PML-NBs might modulate 416 
chromatin architecture and transcription since nascent RNA and several gene loci are 417 
found around PML-NBs (5, 13, 65).  Given this, it seems likely that viruses hijack this 418 
nuclear structure to set up a platform suitable for virus replication.  M1 and NS2 were 419 
shown to be associated with PML-NBs (62, 64), although the functional significance of 420 
the co-localization remains to be determined.  We found that the nuclear-imported 421 
YB-1 accumulates in PML-NBs, in which vRNA was present with M1 and NS2 when 422 
the vRNP export was inhibited (Fig. 2).  Therefore, we speculate that the progeny 423 
vRNPs could be assembled into the export complexes at PML-NBs and subsequently 424 
interact with YB-1.  Additional experiments are needed to clarify a precise role(s) of 425 
PML-NBs in the vRNP nuclear-export as well as the targeting mechanism of YB-1 to 426 
PML-NBs. 427 
 The accumulation of recycling endosome vesicles around MTOC is disrupted 428 
in the presence of microtubule-depolymerization reagents such as nocodazole (8).  429 
Thus, it is likely that the intact microtubule functions as a platform for the recycling 430 
endosome vesicle.  We observed a direct binding of YB-1 with vRNP for the 431 
recruitment of vRNP to microtubules (Fig. 7).  However, only a small portion of vRNP 432 
was co-localized with YB-1 in infected cells, suggesting that YB-1 transiently interacts 433 
with vRNP (Fig. 1).  Further, we could not find YB-1 in the purified influenza virions 434 
(data not shown), suggesting that YB-1 might be dissociated from vRNP prior to 435 
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packaging of vRNP into progeny virions.  The association between YB-1 and enough 436 
amounts of microtubules is proposed to compete with the interaction of YB-1 with 437 
cellular mRNP in vitro (11).  Thus, we speculate that vRNP-YB-1 complexes recruited 438 
on microtubules may be disassembled by the microtubule formation, and thereby vRNP 439 
could be loaded onto Rab11a-positive recycling endosomes bound to microtubules. 440 
The Rab11a-mediated vesicular transport may be functionally important after 441 
arriving at the plasma membrane.  For example, the lipid rafts are required for the 442 
budding of influenza virus from the apical plasma membrane (63, 70), and cholesterol, 443 
an essential component of the lipid rafts, is enriched in the recycling endosome 444 
membrane (48).  Interestingly, it is shown that influenza virus particles are hardly 445 
pinched off from the plasma membranein Rab11a KD cells (7).  Thus, it is possible 446 
that the Rab11a-positive recycling endosome has an important role in the apical 447 
transport of proteins and/or membranes, which are involved in budding process 448 
including membrane scission (60).  However, it is also possible that the trafficking of 449 
the viral genome is required to allow the efficient virus budding.  The influenza virus 450 
genome consists of eight-segmented vRNA molecules.  Since it is believed that the 451 
eight individual segments are packaged into a progeny virion (53), a hierarchical 452 
incorporation of each vRNA should be required.  It is hypothesized that 453 
Rab11a-positive transport vesicles might be an assembly center of eight segments of 454 
vRNA (17, 47).  To further understand the mechanism of influenza virus egress, the 455 
dynamics of the recycling endocytic compartment is to be analyzed. 456 
 457 
 458 
459 
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FIGURE LEGENDS 741 
 742 
FIG 1  Identification of YB-1 as a novel vRNP-interacting proteins.  (A) 743 
Identification of cellular and viral proteins interacting with vRNP complexes.  HeLa 744 
cells infected with influenza virus at moi of 10 were subjected to immunoprecipitation 745 
assays with control IgG- (lane 2) or anti-NP (lane 3) antibody-conjugated protein 746 
A-Sepharose.  The co-precipitated proteins were eluted in 100 mM glycine (pH 2.8), 747 
separated through 10% SDS-PAGE, and visualized by silver staining.  Molecular 748 
weight markers are also shown in lane 1.  (B) Intracellular localization of YB-1 in 749 
infected cells.  Infected MDCK cells were subjected to indirect immunofluorescence 750 
assays with anti-YB-1 antibody followed by FISH assays using a probe that hybridizes 751 
with segment 1 vRNA at 0, 4, 8, and 12 hpi.  For LMB treatment, infected cells were 752 
incubated in culture medium containing 20 nM LMB at 7 hpi, and then the intracellular 753 
localization of vRNA and YB-1 was visualized by FISH and indirect 754 
immunofluorescence assays at 12 hpi.  The result of SeV-infected cells at 12 hpi is also 755 
shown.  Scale bar, 10 m.  (C) Intracellular localization of cellular proteins related to 756 
P-bodies and SGs.  Mock-infected (left panels) or infected MDCK cells at 8 hpi (right 757 
panels) were subjected to indirect immunofluorescence assays with anti-RAP55 (upper 758 
panels, red), anti-RCK (middle panels, red), and anti-TIAR (lower panels, red) 759 
antibodies, respectively.  Nuclear DNA was stained with TO-PRO-3 iodide (blue).  760 
Scale bar, 10 m. 761 
 762 
FIG 2  Co-localization of YB-1 and vRNP export complexes in nuclear speckles.  (A) 763 
Intracellular localization of YB-1, M1, and NS2.  At 8 hpi, infected MDCK cells were 764 
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subjected to indirect immunofluorescence assays with rabbit anti-YB-1 (red) and either 765 
mouse anti-M1 (upper panel, green) or rat anti-NS2 (lower panel, green) antibody.  766 
Scale bar, 10 m.  (B) Intracellular localization of vRNA, YB-1, M1, and NS2 in the 767 
presence of LMB.  At 7 hpi, infected MDCK cells were incubated for 1 h in the 768 
presence of 20 nM of LMB.  Segment 1 vRNA (left panels, green), YB-1 (upper panel, 769 
red), M1 (middle panel, red), and NS2 (lower panel, red) were visualized by FISH and 770 
indirect immunofluorescence assays, respectively.  Scale bar, 10 m.  (C) 771 
Accumulation of vRNA and YB-1 in PML-NBs in the presence of LMB.  After 772 
treatment of LMB as described in panel B, mock-infected (upper panel) and infected 773 
(middle and lower panels) MDCK cells were subjected to FISH assays using the probe 774 
that hybridizes with segment 1 vRNA (upper and middle panels, green) and the indirect 775 
immunofluorescence assays with rabbit (upper and middle panels, red) and mouse 776 
(lower panel, red) anti-PML and rabbit anti-YB-1 antibodies (lower panel, green), 777 
respectively.  Scale bar, 10 m. 778 
 779 
FIG 3  Specific interaction of YB-1 with vRNA but neither cRNA nor viral mRNA.  780 
(A) Intracellular localization of YB-1 and viral mRNA/cRNA.  At 8 hpi, infected 781 
MDCK cells were subjected to FISH assays using a probe that hybridizes with segment 782 
1 cRNA and mRNA (green) and indirect immunofluorescence assays with anti-YB-1 783 
antibody (red) with or without 20 nM LMB treatment for 1 h.  Nuclear DNA was 784 
stained with TO-PRO-3 iodide (blue).  Scale bar, 10 m.  (B) 785 
Co-immunoprecipitation of YB-1 and viral RNA molecules.  HeLa cells constitutively 786 
expressing FLAG-YB-1 were infected with influenza virus at moi of 10.  After 8 hpi, 787 
cell lysates were prepared and subjected to immunoprecipitation assays in the presence 788 
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of either control IgG or anti-FLAG antibody as described in Methods.  The 789 
immunoprecipitated viral RNAs were eluted with 100 g/ml FLAG peptide, and then 790 
quantitatively analyzed by reverse transcription followed by real-time PCR with primers 791 
specific for segment 5 vRNA, cRNA, and NP mRNA, respectively.  To quantitatively 792 
evaluate, 5%-equivalents of mock-infected and infected samples were also observed. 793 
 794 
FIG 4  Accumulation of YB-1-vRNP complexes on microtubules with 795 
Rab11a-positive recycling endosomes in response to infection.  (A) Co-localization of 796 
YB-1 and microtubules in cytoplasmic punctate signals.  At 12 hpi, mock-infected 797 
(upper panels) and infected MDCK cells (lower panels) were subjected to indirect 798 
immunofluorescence assays with anti-YB-1 (red) and -tubulin (green) antibodies.  799 
Scale bar, 10 m.  (B and C) Interaction of YB-1 with Rab11a-positive recycling 800 
endosomes on microtubules.  HeLa cells constitutively expressing FLAG-YB-1 were 801 
infected with influenza virus at moi of 10.  Cell lysates were prepared and subjected to 802 
immunoprecipitation assays in the presence of either control IgG (panel B, lanes 2 and 803 
5) or anti-FLAG antibody (panel B, lanes 3 and 6) at 12 hpi.  Co-precipitated proteins 804 
were eluted with 100 g/ml FLAG peptide and detected by western blotting assays with 805 
anti-PB1, anti-Rab11a, anti--tubulin, and anti-FLAG antibodies.  The 806 
10%-equivalents of mock-infected (panel B, lane 1) and infected lysates (panel B, lane 807 
4) were also subjected to western blotting assays.  Further, the eluate purified from 808 
infected lysate (panel B, lane 6) was re-immunoprecipitated with either control IgG 809 
(panel C, lane 2) or anti-NP antibody (panel C, lane 3), and then the eluate was 810 
subjected to western blotting assays with anti--tubulin and anti-Rab11a antibodies.  811 
Panel C, lane 1 represents the 30%-equivalent of proteins immunopurified with 812 
 34
anti-FLAG antibody from infected cell lysate. 813 
 814 
FIG 5  The effect of YB-1 overexpression on the production of infectious virions.  815 
(A) Expression level of YB-1 and Rab11a proteins.  293T cells were transfected with 816 
either pCAGGS empty plasmid (lanes 1 and 3) or pCAGGS-FLAG-YB-1 (lanes 2 and 817 
4) after 24 h post treatment of either non-targeting (control; lanes 1 and 2) or Rab11a 818 
siRNA (siRab11a; lanes 3 and 4).  After 24 h post transfection of expression vectors, 819 
the cell lysates were prepared and analyzed by SDS-PAGE followed by western blotting 820 
assays with anti-YB-1, anti-Rab11a, and anti--actin antibodies.  (B) The 821 
accumulation level of viral proteins in cells overexpressing FLAG-YB-1.  293T cells 822 
were transfected with either pCAGGS or pCAGGS-FLAG-YB-1.  At 24 h post 823 
transfection, cells were infected with influenza virus at moi of 10.  At 0, 2, 5, and 8 hpi, 824 
cell lysates were prepared and analyzed by western blotting assays with anti-PB1, 825 
anti-NP, anti-M1, anti-NS2, and anti--tubulin antibodies.  (C) Production of 826 
infectious virions.  Control (open diamonds and filled squares) and Rab11a KD 293T 827 
(open triangles and open squares) cells transfected with either pCAGGS (open 828 
diamonds and open triangles) or pCAGGS-FLAG-YB-1 (filled and open squares) as 829 
described in panel A were infected with influenza virus at moi of 0.5.  The culture 830 
supernatants collected at 3, 6, 12, 16, 20, and 24 hpi were subjected to plaque assays to 831 
examine the production of infectious virions in a single-round infection.  The average 832 
titers and standard deviations determined from three independent experiments are 833 
shown.  (D) Stimulatory activity of YB-1 on the virus titer in Rab11a KD cells.  The 834 
slopes of the lines in panel C were determined by the least-square method, and the ratio 835 
of the virus titer from cells overexpressing FLAG-YB-1 to that from cells transfected 836 
 35
with pCAGGS is shown. 837 
 838 
FIG 6  Acumulation of vRNP on microtubules in YB-1 knockdown cells.  (A) The 839 
expression level of YB-1 in YB-1 KD cells.  HeLa cells transfected with non-targeting 840 
(Control; lanes 1-4) or YB-1 siRNA (siYB-1; lanes 5-8) were lysed, and then the lysates 841 
(2.5 x 103, 5 x 103, 1 x 104, and 2 x 104 cells) were subjected to SDS-PAGE followed by 842 
western blotting assays with anti-YB-1 antibody at 48 h post transfection.  (B and C) 843 
The accumulation level of viral proteins and RNAs in YB-1 KD cells.  At 48 post 844 
transfection of siRNA, control and YB-1 KD cells were infected with influenza virus at 845 
moi of 10.  After 0, 2, 5, and 8 hpi, cell lysates were prepared and analyzed by western 846 
blotting assays with anti-PB1, anti-NP, anti-M1, anti-NS2, and anti--tubulin antibodies 847 
(panel B).  Total RNAs purified from the cells at 0, 2, 5, and 8 hpi were subjected to 848 
reverse transcription followed by quantitative real-time PCR with primers specific for 849 
segment 5 vRNA and NP mRNA as described in Materials and Methods.  (D and E) 850 
Intracellular localization of vRNA in YB-1 KD cells.  At 8 hpi with or without LMB 851 
treatment for 1 h, infected control and YB-1 KD cells were subjected to FISH assays 852 
using a probe that hybridizes with segment 1 vRNA (panel D; scale bar=10 m).  Cells 853 
were counted, and the localization pattern of vRNA in the absence of LMB was 854 
determined (panel E).  The number of cells showing each localization pattern was 855 
expressed as the percentage of the total cell number (n=80) in panel E.  The average 856 
percentages determined from three independent experiments are shown 857 
 858 
FIG 7  YB-1 functions as a porter bringing the progeny vRNP to microtubules.  (A) 859 
Direct interaction of YB-1 with viral polymerase complex.  The vRNP (lanes 4-6) or 860 
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micrococcal nuclease-treated vRNP (mnRNP; lanes 7-9) were incubated in the absence 861 
(lanes 2, 5, and 8) or presence of purified recombinant His-YB-1 protein (lanes 3, 6, and 862 
9) at 30ºC for 1 h.  Complexes were purified using Ni-NTA resin, and then proteins 863 
were separated through SDS-PAGE and detected by CBB staining and western blotting 864 
assays with anti-PB1, anti-PB2, and anti-PA antibodies.  Lanes 1, 4, and 7 represent 865 
20% of input amounts.  (B) Interaction of vRNP with deletion mutants of YB-1.  866 
Each GST-fused deletion mutant of YB-1 was incubated with vRNP at 30ºC for 1 h.  867 
Complexes were purified using glutathione-Sepharose resins, and then proteins were 868 
separated through SDS-PAGE and detected by western blotting assays using anti-PB1 869 
antibody.  Lane 1 represents 20% of input amounts.  Schematic diagram of the 870 
deletion mutants of YB-1 is indicated at the bottom.   (C) The interaction between 871 
vRNP and microtubules mediated by YB-1.  Reconstituted microtubules were 872 
incubated with either vRNP (lanes 2 and 4) or YB-1-vRNP complex (lanes 3 and 5), and 873 
then complexes were immunoprecipitated with either a non-specific IgG (control; lanes 874 
2 and 3) or anti-NP antibody (lanes 4 and 5).  The immunoprecipitated proteins were 875 
separated through SDS-PAGE and subjected to western blotting assays with 876 
anti--tubulin and anti-NP antibodies.  Lane 1 represents 10% of input amount.  (D) 877 
Interaction of vRNP with microtubules in YB-1 KD cells.  HeLa cells constitutively 878 
expressing FLAG--tubulin were infected with influenza virus at moi of 10.  At 8 hpi, 879 
the cell lysates were prepared and subjected to immunoprecipitation assays with either 880 
control IgG or anti-FLAG antibody.  The immunoprecipitated proteins eluted with 100 881 
g/ml FLAG peptide were separated through SDS-PAGE, and then visualized by 882 
western blotting assays using anti-PB1 and anti--tubulin antibodies.  The 883 
5%-equivalents of control (lane 1) and YB-1 KD lysates (lane 4) are also shown.884 
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Table 1.  LC-MS analysis of vRNP-interacting proteins. 885 
Protein name No. of observed peptides
Mascot score Sequence coverage (%) 
Heterogenous nuclear ribonucleorpotein A1 6 85 9 
Heterogeneous nuclear ribonucleoproteins 
C1/C2 
11 64 21 
Heterogeneous nuclear ribonucleoprotein D0 4 77 12 
Heterogeneous nuclear ribonucleoprotein H 9 159 17 
Heterogeneous nuclear ribonucleoprotein H2 8 111 17 
Heterogeneous nuclear ribonucleoprotein L 7 98 17 
ATP-dependent RNA helicase DDX3Y 15 80 17 
ATP-dependent RNA helicase DDX5 7 81 10 
ATP-dependent RNA helicase DDX17 10 87 12 
Nucleolin 8 85 13 
78 kDa glucose-regulated protein 11 157 15 
Importin subunit alpha-7 3 65 8 
Y-box binding protein-1 3 91 10 
Tubulin alpha-1C chain 5 70 12 
Spliceosome RNA helicase UAP56 5 62 10 
Heat shock protein 90 alpha 9 111 15 
Heat shock protein 90 beta 9 73 14 
Heat shock cognate 71 kDa protein 11 134 15 
Heat shock 70 kDa protein 1 12 120 14 
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